Leading Dutch crypto exchange LiteBit partners with RIDDLE&CODE to pave the way towards regulatory compliance and launch the next generation of crypto services
13.4.2021 11:15:00 EEST | Business Wire | Press release
RIDDLE&CODE FinTech Solutions, an innovative European company that empowers financial institutions to handle all aspects of digital asset management, announced today that LiteBit, the leading Dutch cryptocurrency exchange, has chosen its Token Management Platform (TMP) to scale infrastructure, respond to regulatory requirements and provide advanced capabilities to its growing customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005034/en/
Over the last few years, the European Union has significantly tightened its regulations on crypto service providers, including the recently updated 5th Anti-Money Laundering Directive (AMLD5). The newly implemented AMLD5 guidelines oblige service providers such as crypto exchanges and custodians to adhere to the same regulatory provisions as traditional financial institutions.
“The Dutch implementation of the regulations currently goes beyond EU guidelines and calls for extensive identification of customers and monitoring of transactions as well as extensive reporting and audit capabilities,” said Berit Fuss, Director of FinTech Solutions at RIDDLE&CODE. “These requirements have turned out to be quite burdensome and have forced several crypto-related businesses to close or leave the Netherlands.”
“Crypto exchanges across the industry are prioritising compliance with regulatory obligations. LiteBit is no exception,” said Arthur Van Lier, LiteBit’s COO. “The partnership with RIDDLE&CODE and the use of the cutting-edge TMP enables us to be compliant with both current and future regulations. But regulatory frameworks aren’t the only ones evolving,” he added. “At the moment, Decentralised Finance (DeFi) is one of the fastest-growing sectors in the crypto industry. However, due to the complexity of the applications and the efforts required to support several token protocols, many market players struggle to innovate and accommodate the integration of DeFi capabilities. With the TMP, we can benefit from these new business models and scale our operational capabilities.”
The TMP provides the Dutch exchange with a robust and transparent foundation for:
- Responding to the most pressing demands in an ever-changing regulatory environment, including AML/CFT requirements, customer due diligence, Know-Your-Customer (KYC) procedures and more.
- Scaling its operations by creating unlimited segregated accounts for its customers and automating certain processes to reduce the burden on the operational teams.
- Being flexible enough to offer DeFi services such as staking or voting on popular networks like Polkadot and Ethereum.
The Token Management Platform is the next generation of RIDDLE&CODE’s institutional-grade digital asset management solution. The cloud-based platform manages all aspects of key generation, custody, AML, regulatory compliance and token management. Accepted by the Swiss financial market authorities, the TMP is fully auditable and compliant with financial regulations, allowing clients to fulfill all transparency requirements in line with financial regulations and internal compliance policies.
“We are thrilled to work with LiteBit, our first crypto exchange customer,” said Alexander Koppel, CEO of RIDDLE&CODE. “This strategic partnership allows us to enter the Dutch market and help LiteBit in its journey to full regulatory compliance and expansion across Europe.”
RIDDLE&CODE FinTech Solutions
RIDDLE&CODE FinTech solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, builds hardware and software stacks that empower funds, crypto exchanges and regulated financial institutions to manage all aspects of key generation, custody, AML, regulatory compliance and token management with unmatched versatility and security.
LiteBit
LiteBit is a platform that makes trading in crypto safe, simple and personal. Its aim is to be the most customer-friendly and reliable platform in Europe. LiteBit supports investors in buying, selling and managing crypto, such as Bitcoin, Ethereum and more than 50 other types of coins.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005034/en/
Contact information
Media contact:
Aysenur Yükselal Aji
aysenur@riddleandcode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom